SAB Biotherapeutics, Inc., (SABS) Social Stream
SAB BIOTHERAPEUTICS INC (SABS) Price Targets From Analysts
Use the tables below to see what analysts covering SAB BIOTHERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-23 | 4 | $23 | $16.5 | $18.625 | $0.689 | 2603.19% |
| 2021-12-02 | 4 | $23 | $16.5 | $19.375 | $0.689 | 2712.05% |
| 2022-03-31 | 4 | $23 | $9 | $16.375 | $0.689 | 2276.63% |
| 2022-04-04 | 4 | $23 | $9 | $14.625 | $0.689 | 2022.64% |
| 2022-04-06 | 4 | $23 | $9 | $14.1 | $0.689 | 1946.44% |
| 2022-05-15 | 4 | $23 | $7 | $13.35 | $0.689 | 1837.59% |
| 2022-05-17 | 4 | $23 | $7 | $12.85 | $0.689 | 1765.02% |
| 2022-08-11 | 4 | $12.4 | $3 | $7.1 | $0.689 | 930.48% |
| 2022-08-23 | 3 | $9 | $3 | $6.062 | $0.689 | 779.83% |
| 2022-11-16 | 2 | $9 | $3 | $6.062 | $0.689 | 779.83% |
| 2022-11-21 | 2 | $9 | $3 | $5.75 | $0.689 | 734.54% |
| 2023-01-18 | 3 | $9 | $3 | $5.4 | $0.689 | 683.74% |
| 2023-04-18 | 3 | $7 | $3 | $4.5 | $0.689 | 553.12% |
| 2023-05-17 | 3 | $4 | $3 | $3.6 | $0.689 | 422.5% |
| 2023-05-26 | 3 | $4 | $2.6 | $3.4 | $0.689 | 393.47% |
| 2023-08-22 | 3 | $3 | $2 | $2.533 | $0.689 | 267.63% |
| 2023-10-06 | 3 | $3 | $2 | $2.5 | $0.689 | 262.84% |
| 2023-11-15 | 3 | $3 | $1 | $2 | $0.689 | 190.28% |
The Trend in the Analyst Price Target
Over the past 25 months, SABS's average price target has gone down $16.62.
SABS reports an average of 312.43% for its upside potential over the past 43 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-18 | 3 | 9 | 3 | 5.4 | 0.729 | 640.74% |
| 2023-04-18 | 3 | 4 | 3 | 3.6 | 1.090 | 230.28% |
| 2023-05-17 | 3 | 4 | 3 | 3.6 | 0.851 | 323.03% |
| 2023-10-06 | 3 | 3 | 2 | 2.5 | 0.660 | 278.79% |
| 2023-11-15 | 3 | 3 | 1 | 2.0 | 0.910 | 119.78% |
SABS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.67 | 2 | 0 | 1 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
SABS's average broker recommendation rating worsened by 0.67 over the prior 26 weeks.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, SAB BIOTHERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 2004.84% of them.
- SAB BIOTHERAPEUTICS INC's average analyst price target is greater than 184.36% of all US stocks.
- SABS has a greater number of analysts covering the stock than 199.61% of all US stocks.
- In terms of how SAB BIOTHERAPEUTICS INC fares relative to Healthcare stocks, note that its variance in analysts' estimates is lower than -1207.71% of that group.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to SAB BIOTHERAPEUTICS INC are MOLN, SOPH, and CDXC.
View All Top Stocks by Price Target
Make investment decisions regarding SABS using the data that counts. Try POWR Ratings for free.